Our findings suggest that FABP3 is a novel molecular target for the development of α-synucleinopathy therapeutics and that an FABP inhibitor such as MF1 is an attractive candidate to treat patients with PD and/or DLB. Here, FABP3 is linked to Lewy body dementia.